Additional insights into pergolide-associated valvular heart disease

被引：12

作者：

Lanier, WL

机构：

[1] Mayo Clin Proceedings, Rochester, MN 55905 USA

[2] Mayo Clin Proceedings, Dept Anesthesiol, Rochester, MN 55905 USA

来源：

MAYO CLINIC PROCEEDINGS | 2003年 / 78卷 / 06期

关键词：

FENFLURAMINE; PHENTERMINE; TIME;

D O I：

10.4065/78.6.684

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：684 / 686

页数：3

共 8 条

[1] MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].

BOESS, FG ;

MARTIN, IL .

NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317

[2] Valvular heart disease associated with fenfluramine-phentermine [J].

Connolly, HM ;

Crary, JL ;

McGoon, MD ;

Hensrud, DD ;

Edwards, BS ;

Edwards, WD ;

Schaff, HV .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588

[3] The US Food and Drug Administration's registry of patients with pergolide-associated valuvular heart disease [J].

Flowers, CM ;

Racoosin, JA ;

Lu, SL ;

Beitz, JG .

MAYO CLINIC PROCEEDINGS, 2003, 78 (06) :730-731

[4] Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine [J].

Hensrud, DD ;

Connolly, HM ;

Grogan, M ;

Miller, FA ;

Bailey, KR ;

Jensen, MD .

MAYO CLINIC PROCEEDINGS, 1999, 74 (12) :1191-1197

[5]

*MED EC CO INC, 2001, PHYS DESK REF, P668

[6] VaIvular heart disease in patients taking pergolide [J].

Pritchett, AM ;

Morrison, JF ;

Edwards, WD ;

Schaff, HV ;

Connolly, HM ;

Espinosa, RE .

MAYO CLINIC PROCEEDINGS, 2002, 77 (12) :1280-1286

[7] Drug-related valvular heart disease: Here we go again: Will we do better this time? [J].

Rahimtoola, SH .

MAYO CLINIC PROCEEDINGS, 2002, 77 (12) :1275-1277

[8]

Teramae CY, 2000, MAYO CLIN PROC, V75, P456

← 1 →